Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Finished Goods: 2021-2024

  • Ascendis Pharma A's Finished Goods rose 117.41% to $45.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was $45.2 million, marking a year-over-year increase of 117.41%. This contributed to the annual value of $45.8 million for FY2024, which is 120.21% up from last year.
  • As of Q4 2024, Ascendis Pharma A's Finished Goods stood at $45.2 million, which was up 117.41% from $20.8 million recorded in Q4 2023.
  • Ascendis Pharma A's 5-year Finished Goods high stood at $45.2 million for Q4 2024, and its period low was $4.9 million during Q4 2021.
  • Moreover, its 3-year median value for Finished Goods was $20.8 million (2023), whereas its average is $24.8 million.
  • Data for Ascendis Pharma A's Finished Goods shows a peak YoY skyrocketed of 149.52% (in 2023) over the last 5 years.
  • Ascendis Pharma A's Finished Goods (Quarterly) stood at $4.9 million in 2021, then soared by 69.81% to $8.3 million in 2022, then soared by 149.52% to $20.8 million in 2023, then soared by 117.41% to $45.2 million in 2024.
  • Its last three reported values are $45.2 million in Q4 2024, $20.8 million for Q4 2023, and $8.3 million during Q4 2022.